Piccina Cintia 4

4 · Adaptimmune Therapeutics PLC · Filed Jan 31, 2022

Form 4

Period: 2022-01-31

Chief Commercial Officer

Transactions

Award
Option to purchase Ordinary Shares
2022-01-31+3,376,992→ 3,376,992 total
Exercise: $0.45Exp: 2032-01-31→ Ordinary Shares (3,376,992 underlying)
Award
Option to purchase Ordinary Shares
2022-01-31+335,184→ 335,184 total
Exercise: $0.00From: 2022-07-31Exp: 2023-03-15→ Ordinary Shares (335,184 underlying)
Award
Option to purchase Ordinary Shares
2022-01-31+754,200→ 754,200 total
Exercise: $0.00→ Ordinary Shares (754,200 underlying)

Footnotes (6)

[F1]The exercise price was converted from GBP0.33 based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.
[F2]Exercisable as to 844,248 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in monthly installments of 70,350 Ordinary Shares on the last day of each month from February 28, 2023 through December 31, 2025 and 70,494 Ordinary Shares on January 31, 2026.
[F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.
[F4]Exercisable as to 188,550 Ordinary Shares on January 31, 2023 and will be exercisable as to the remainder in annual installments of 188,550 Ordinary Shares on the thirty-first of each January from January 31, 2024 through January 31, 2026.
[F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
[F6]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$1.34145 to GBP1.00. The actual exercise price will be the pounds sterling amount.

Documents

1 file